Dana Boyle
Known title: Chief Accounting OfficerCIK: 0002074453
Associated companies
Transaction History
| LQDA | ▼ Sell | Open Market | 1,600 | $140K | 7/27/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 641 | $46K | 7/13/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 8,361 | $598K | 7/13/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,179 | — | 7/10/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,576 | $60K | 4/27/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 5,101 | $196K | 4/13/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,179 | — | 4/10/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 445 | $14K | 3/2/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,580 | $66K | 1/26/2026 | View on chart |
| LQDA | ▲ Buy | Grant | 23,728 | $0 | 1/16/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 11,047 | $413K | 1/12/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 12,716 | — | 1/9/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 303 | $10K | 12/1/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 8,342 | $210K | 11/7/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 20,662 | $518K | 11/7/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,073 | $25K | 10/27/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,238 | $29K | 10/13/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 296 | $9K | 8/29/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,063 | $21K | 7/28/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,193 | $17K | 7/14/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 25,000 | $0 | 7/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.